Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Zuccala, A.
Right arrow Articles by Zucchelli, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zuccala, A.
Right arrow Articles by Zucchelli, P.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrology Dialysis Transplantation, Vol 13, Issue 90008 26-29, Copyright © 1998 by Oxford University Press


ORIGINAL ARTICLES

Renovascular disease in diabetes mellitus: treatment by percutaneous transluminal renal angioplasty

A Zuccala, F Losinno, A Zucchelli and P Zucchelli
Divisone di Nefrologia e Dialisi Malpighi and Servizio di Radiologia, Policlinico S Orsola-Malpighi, Via P Palagi, 9, 40138 Bologna, Italy; Corresponding author

Background: Diabetes mellitus is an important cause of end-stage renal failure (ESRF). Although classic diabetic nephropathy accounts for the majority of patients reaching ESRF, renovascular disease, which is frequent in such patients, plays an increasingly important role. Percutaneous transluminal renal angioplasty (PTRA) has been proven to be an efficacious measure for renal revascularization.Methods: Ninety-nine patients with diabetes mellitus and renal artery stenosis, corresponding to 16.6% of the entire population of diabetic patients, were treated by PTRA or with the Palmaz-Schatz stent in our clinic. Technical success was achieved by PTRA in 92/99 patients, in 10 patients a Palmaz-Schatz stent was implanted.Results: Hypertension was cured in eight and improved in 44 patients. In 47 patients, there was no impact on blood pressure. An improvement in renal function was evident 1 month after PTRA in 8/27 patients. A further improvement occurred in another four patients after 6 months. The re-stenosis rate was 22% after 5 years. Serious complications occurred in seven patients (one patient required surgery and two patients had regular dialysis treatment).Conclusions: Renovascular disease is an important cause of ESRF in diabetic patients. PTRA is a valid tool to revascularize renal artery stenosis and improve blood pressure control and renal function both in diabetic and non-diabetic patients.Key words: diabetes mellitus; hypertension; intravascular stent; percutaneous transluminal angioplasty; renal insufficiency; renovascular disease
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
QJMHome page
A. Karagiannis, K. Tziomalos, K. Dona, A. Pyrpasopoulou, N. Kartali, V. Athyros, and C. Zamboulis
Bilateral renal artery stenosis and primary aldosteronism in a diabetic patient
QJM, December 1, 2005; 98(12): 913 - 915.
[Full Text] [PDF]


Home page
British Journal of Diabetes & Vascular DiseaseHome page
C. J Hay and P. A Kalra
Review: Renovascular disease in diabetic patients
The British Journal of Diabetes & Vascular Disease, March 1, 2002; 2(2): 91 - 95.
[Abstract] [PDF]


Home page
Nephrol Dial TransplantHome page
N. Zerrenthin
Relationship of renal dysfunction to proximal arterial disease severity in atherosclerotic renovascular disease
Nephrol. Dial. Transplant., June 1, 2001; 16(6): 1300 - 1301.
[Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.